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Abstract
Bladder cancer is the ninth most common malignancy in the world. Successful clinical management
remains a challenge. In order To search for novel targeted and efficacious treatment, we sought to
investigate anti-tumor activity of BI-TK suicide gene therapy system in a rat model of bladder
tumors. We first constructed and tested an anaerobic Bifidobacterium infantis-mediated thymidine
kinase (BI-TK) suicide gene therapy system. To test the in vivo efficacy of this system, we
established a rat model of bladder tumors, which was induced by N-methyl-nitrosourea perfusion.
Bifidobacterium infantis containing the HSV-TK (i.e., BI-TK) were constructed by transformation
of recombinant plasmid pGEX - TK. The engineered BI-TK was injected into tumor-bearing rats
via tail vein, followed by intraperitoneal injection of ganciclovir (GCV). Using the rat model of
bladder tumors, we found that bladder tumor burdens were significantly lower in the rats treated
with BI-TK/GCV group than that treated with normal saline control group (p <0.05). While various
degrees of apoptosis of the tumor cells were detected in all groups using in situ TUNEL assay,
apoptosis was mostly notable in the BI-TK/GCV treatment group. Immunohistochemical staining
further demonstrated that the BI-TK/GCV treatment group had the highest level of caspase3
protein expression than that of the empty plasmid group and normal saline group (p < 0.05). Thus,
our results demonstrate that the Bifidobacterium infantis-mediated TK/GCV suicide gene therapy
system can effectively inhibit rat bladder tumor growth, possibly through increasing caspase 3
expression and inducing apoptosis.
Introduction
Bladder cancer is the ninth most common malignancy in
the world. Current treatments for bladder cancer include
surgery, immunotherapy, chemotherapy and radiother-
apy. There is an increasing trend towards multimodal
treatments. Although there have been substantial changes
in the therapeutic options for the management of both
superficial and muscle-invasive bladder cancer in the last
10 years, successful clinical management still posses a
challenge for urologists and oncologists due to the high
rate for recurrence and progression. It is conceivable that
the efficacy of treatment may significantly be improved by
targeted and/or advanced drug delivery strategies, which
may result in increased treatment specificity together with
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lower toxic potential and higher therapeutic indices.
Novel therapeutic modalities under investigation include
DNA vaccines, magnetically targeted carriers, bio-adhe-
sive microspheres and antisense oligodeoxynucleotides.
For muscle-invasive bladder cancer, perioperative chemo-
therapy is used with increasing frequency. The latest pre-
clinical research efforts are focused on the inhibition of
angiogenesis and other processes predisposing to meta-
static disease.
Cancer gene therapy is an important and promising area
of cancer research. The development of a tumor-specific
targeting tumor gene transfer system is the key to the suc-
cess of gene therapy technique. It has been shown that
Bifidobacterium infantis can specifically target the anaer-
obic tumor cells, and hence is a good tumor - targeting
gene therapy vector system. Herpes Simplex Virus Thymi-
dine kinase/ganciclovir (HSV-TK/GCV) system is cur-
rently one of the best studied tumor suicide gene therapy
system. The thymidine kinase expressed specifically in
tumor tissues can convert the non-toxic precursor ganci-
clovir into the ganciclovir-3-phosphate, a toxic substance
that kills tumor cells. In this study, we developed and val-
idated a novel suicide gene therapy system by exploring
the hypoxic environment of solid tumors and the anaero-
bic metabolism features of Bifidobacterium infantis bacte-
rial cells. Our results have demonstrated that the
Bifidobacterium infantis/thymidine kinase suicide gene
therapy system may be used as a targeted cancer therapy
[1-5].
Currently animal models of bladder tumors are mostly
limited to the use of xenograft tumor models with subcu-
taneous or planting bladder tumor cells. Subcutaneous
xenograft tumor models are most commonly used
because of many advantages, such as easy to establish and
convenient to observe. However, these models neglect the
anatomical and physiological characteristics of cancer-
derived organs. In this study, we conducted MNU
(methyl-nitroso-urea) reperfusion and induced rat blad-
der tumors with a high success rate. The morphological
features and pathological features of the induced tumors
are very similar to that of human bladder tumors, which
come from the bladder epithelia. Histological examina-
tion confirmed that the induced tumors are transitional
cell cancer in nature. MNU-induced bladder cancer seem-
ingly has organ specificity. Thus, this method may repre-
sent an ideal approach to the development and treatment
of bladder cancer [2,3]. Using this model, we investigated
the in vivo efficacy of Bifidobacterium infantis-TK/GCV
suicide gene therapy system in treating bladder tumors in
rats. Our results have demonstrated that the Bifidobacte-
rium infantis-mediated TK/GCV suicide gene therapy sys-
tem can effectively inhibit rat bladder tumor growth via
increasing caspase 3 expression and inducing apoptosis.
Materials and methods
Construction of the Bifidobacterium infantis -mediated 
TK/GCV suicide gene therapy system
Herpes simplex virus - thymidine kinase (HSV - TK) gene
was PCR amplified and subcloned into pGEX-5X-1, at
BamH I and Sal I sites (Takara, Tokyo, Japan), resulting in
pGEX-TK. Potential recombinants were first screened by
bacterial colony PCR, followed by DNA sequencing verifi-
cation. After verification, pGEX-TK plasmid was used to
transform electrocompetent Bifidobacterium infantis bac-
terial cells via electroporation, as previously reported [6-
11].
Experimental animals
Sprague-Dawley (SD) rats (6-8 weeks age, female, weigh-
ing 200-250 g) were housed at the Laboratory Animal
Center of Chongqing Medical University, Chongqing,
China. The animal experiments followed institutional
guidelines for the use and care of animals. Animals were
housed in microisolator cages under a specific pathogen-
free (SPF) condition with 12-hour light-dark cycles.
Bacterial strains and cultivation
Bifidobacterium infantis (Sangon, Shanghai, China) was
provided by Molecular Biology Laboratory of Chongqing
Medical University. Bifidobacterium infantis bacterial
cells were inoculated in MRS (De Man, Rogosa and Sharpe
medium) liquid medium, and grown in an anaerobic tank
with a mixed-gas (80% N2, 10% CO2, 10% H2) at 37°C
overnight.
Establishment of a rat model of bladder cancer 
andexperimental groups
A rat model of bladder tumor was induced by using MNU
(USA, Jersey, Sigma). Fifty four tumor-bearing SD rats
were randomly divided into three groups: the normal
saline group (n = 18), the Bifidobacterium infantis-pGEX-
5X-1 (n = 18), and the Bifidobacterium infantis-pGEX-TK
(i.e., BI-TK) group (n = 18). Each group was given tail vein
injection of saline, Bifidobacterium infantis-pGEX-5X-1,
or Bifidobacterium infantis-TK (containing 4.4 × 109 Bifi-
dobacterium infantis), once every week for two weeks.
Each group also received daily intraperitoneal injection of
ganciclovir (GCV) (50 mg/kg, Merck, Darmstadt, Ger-
many) for 14 days. On the 15th day after treatment, all
rats were sacrificed by the overdose of ketamine (400 mg/
kg) and xylazine (50 mg/kg) and necropsy was performed.
Total weight of bladders was determined (see below).
Tumor tissues were retrieved and embedded in 4% para-
formaldehyde for hematoxylin-eosin (H & E) staining.
Determination of bladder total weight
After the rats were sacrificed, the bladders were retrieved
by severing the jugular, urethra near the bladder neck and
double ureter close to bladder wall. The bladder anteriorJournal of Experimental & Clinical Cancer Research 2009, 28:155 http://www.jeccr.com/content/28/1/155
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wall was opened for examining bladder tumor formation;
and the liquid was dried with filter papers, The total
weight of the bladder was then determined for all animals
in the study.
Apoptosis of bladder tumor cells determined by TUNEL 
assay
The TUNEL assay was carried out according to the manu-
facturer's instructions (TUNEL kit; Roche, Darmstadt, Ger-
many). Apoptotic cells (approximately 100 cells/field for
three non-overlapping fields) were counted. Apoptosis
index was calculated as the percentage of apoptosis cells
over total counted cells.
Immunohistochemical staining of Caspase3 protein 
expression in bladder tumor cells
Immunohistochemical staining was conducted according
to manufacturer's instructions (Zhongshan Golden Bridge
Inc, Shanghai, China). The tumor sections were probed
with a biotinylated anti-Caspase 3 antibody, followed by
incubation with strapavidin-horseradish peroxidase. The
presence of Caspase 3 protein was visualized by adding
horseradish peroxidase substrate diaminobenzidine solu-
tion. The cells were counterstained with hematoxylin.
Positively staining cells were documented under a light
microscope and quantitatively analyzed by the Image-Pro
Plus Analysis system (Olympus, Tokyo, Japan) from at
least five high power fields. The average value of the inten-
sity of positive staining was defined as positive reaction
area/field area.
Statistical analysis
All the experimental data were processed using the
SPSS11.0 software. The number of samples of analysis of
variance was determined by using SN-K method. α = 0.05.
Results
Construction of a novel Bifidobacterium infantis-mediated 
TK/GCV suicide gene therapy system
The pGEX - TK recombinant vector was transformed into
Bifidobacterium infantis by electroporation, After being
cultured for 72 hours, Bifidobacterium infantis formed
scattered colonies on the LB-plates containing MRS and
ampicillin LB-plates. In contrast, transformatoion wild-
type Bifidobacterium infantis only had no colonies on the
MRS benzyl penicillin LB plates. Single colonies were
picked up and grown under anaerobic condition. DNA
was purified and verified by restriction enzymatic diges-
tion and PCR amplification (Figure 1).
Histologic analysis of rat bladder tumors
As shown in Figure 2A, in the normal saline group tumors
formed wide bases with short stalk structures. Tumor cells
were highly heterogeneous, resembling the characteristics
of human bladder cancers. Malignant cells were shown to
infiltrate focal subtunica mucosa, muscular tunic. In both
BI-pGEX-5X-1 and BI-pGEX-TK groups, the tumors grew
much more slowly than that of the NS group; and tumor
necrosis was more pronounced in these groups (Figures
2B and 2C).
Significant reduction of the total weight of tumor-bearing 
bladders via BI-TK-mediated suicide gene therapy
As shown in Table 1, The bladder cancer occur in rat 9
weeks after MNU reperfusion, we used B-type ultrasonic
inspection to measure the size of the tumor before treat-
ment, the volume is no statistical significance. the total
bladder weight of BI-TK group was significantly lower
than that of the NS group (p <0.01). However, the weight
difference between the NS group and the BI-pGEX-5X-1
group was not statistically different (p  >  0.05). These
results suggest that the BI-TK/GCV tumor-targeting suicide
gene therapy system may significantly inhibit bladder
tumor growth.
Detection of apoptosis in rat bladder tumors
Using the in situ TUNEL method, we found that each
group exhibted varying degrees of apoptosis-staining pos-
itivity (Figure 3). The apoptotic indexes were 14.33 ±
5.29% for the NS group, 15.50 ± 4.34% for BI-pGEX-5X-1
group, and 29.44 ± 6.64% for BI-TK group, respectively.
The apoptotic index for BI-TK group was significantly
Construction and verification of Bifidobacterium infantis- mediated TK tumor-targeting suicide gene therapy system Figure 1
Construction and verification of Bifidobacterium 
infantis-mediated TK tumor-targeting suicide gene 
therapy system. Plasmid DNA was purified from anaerobic 
culture, digested with restriction enzymes, and resolved on 
1% agarose gel. The expected 6.0 kb fragment of pGEX-TK is 
indicated by arrows.
1  2    3   4   5 6
6.0kb 
1.1kb 
Figure1 
Lane1:HindIII Marker 
Lane2:PGEX-TK 
Lane3,4,6:HSV-TK DNA 
Lane5:250 bp Marker Journal of Experimental & Clinical Cancer Research 2009, 28:155 http://www.jeccr.com/content/28/1/155
Page 4 of 7
(page number not for citation purposes)
higher than that of BI-pGEX-5X-1 group or the NS group
(p <0.05). These results indicate that BI-TK/GCV suicide
gene therapy system can kill bladder cancer cells, possibly
through inducing apoptosis.
Caspase 3 protein expression in bladder tumor tissues
We further analyzed the protein levels of caspase 3 in
bladder tumor tissues by immunohistochemistry. Cas-
pase 3 positive staining showed brownish yellow in the
cytoplasm (in some cases, on cell membranes) (Figure 4).
The percentage of positive caspase 3 staining was 41.72 ±
4.27% for the BI-TK group, 16.01 ± 3.48% for the BI-
pGEX-5X-1 group, and 6.88 ± 1.40% for the normal saline
group, respectively. The differences between each group
were statistically significant (p <0.05). Nonetheless, these
findings strongly suggest that BI-TK/GCV gene therapy
system may upregulate Caspase 3 expression in bladder
tumors and hence promote bladder tumor cell apoptosis
(Figure 4).
Discussion
Currently animal models of bladder tumors are mostly
limited to the use of xenograft tumor models with subcu-
taneous or planting bladder tumor cells. Subcutaneous
tumor model is most commonly used because of its easy
manipulation, tumor growth consistency, and easy obser-
vation. However, the subcutaneous xenograft models
ignore the anatomic and physiological characteristics of
the organ. The method of MNU induce tumor have many
good quality: easy, little used, induce way agility, it can be
filling into bladder or injection by vein. Steinberg [12]
evaluate the drug treatment therapeutic efficacy in MNU
induced rat bladder tumor model, the result showed that
the occurrence and biological behaviour is similar
between MNU induced rat bladder tumor model and
human TCCB, so MNU induced rat bladder tumor model
can be used to research the treatment of bladder tumor.
In this study, we demonstrated that MNU reperfusion -
induced rat bladder tumor have a high rate of success
(nearly 100%) with morphological and pathological fea-
tures similar to that of human bladder cancer. At the end-
point of this study, we also examined other organs,
including liver, kidney, heart and lungs, and did not
found any tumor formation, which is consistent with ear-
lier reports [7,13-15]. Tumor-bearing rat was put to death
Histologic evaluation of the MNU-induced rat bladder cancer Figure 2
Histologic evaluation of the MNU-induced rat bladder cancer. MNU-induced bladder tumor samples were retrieved 
and subjected to paraffin-embedded sectioning and H & E staining. (A) Normal saline group, (B) Bifutobacterium infantis with 
empty plasmid group, and (C) Bifutobacterium infantis-PGEX-TK group. Representative samples are shown. Magnification, 
100×.
normal
Saline-group:
HEh100
empty plasmid baby- 
Bifidobacte-rium group 
HEh100
Recombinant
Plasmid baby 
Bifidobacterium group 
HEh100
Table 1: Bladder total weight of all tumor-bearing rat (  ± s, n = 18)
Groups bladder total weight(mg)
NS group 302.33 ± 22.09
PGEX-5X-1- bifutobacterium infantis group 279.55 ± 21.17*
PGEX-TK- bifutobacterium infantis group 245.72 ± 13.34*
With regard to NS groups, *P < 0.05
Recombinant plasmid baby rat bladder bifidobacterium group was significantly lower than the total weight with the other groups, significant 
differences (p < 0.01). there was no significant difference between Saline group with empty plasmid baby Bifidobacterium group (p > 0.05); above 
results show that babies bifidobacterium - TK/GCV system gene targeting therapy can significantly inhibit bladder tumor growth.
xJournal of Experimental & Clinical Cancer Research 2009, 28:155 http://www.jeccr.com/content/28/1/155
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l2 weeks after filling with MNU, cut open the bladder, we
fond that the wall of bladder is thickening, pale and cau-
liflower like neoplasia, most of the bladder have many
neoplasia, the serious one is full of neoplasia in the blad-
der. After 12 weeks, HE stain showed the typical TCCB
(transitional cell carcinoma of the bladder) change
appearance and focal under membrana mucosa, muscular
layer infiltrate of tumor. It seems that the MNU bladder
perfusion induced-cancer has organ specificity; and we
did not find any adenocarcinoma or squamous cell carci-
noma of the bladder histological changes. Therefore,
MNU perfusion may represent an ideal approach for the
establishment of animal models of bladder cancer for
evaluating novel anti-cancer treatments.
Targeted cancer gene therapy is an ideal treatment for
eradicating and/or limiting cancer growth and improving
quality of life and survival rate of cancer patients. HSV-TK/
GCV system is one of the most commonly used suicide
gene therapy systems. However, most studies have used
viral expression vectors, such as adenoviral or retroviral
vectors to achieve the TK gene expression. Although effi-
cient, these viral delivery systems have their own limita-
tions, such as host immune response, low titer, the
limited host range, serum complement inactivation, and
detrimental mutations caused by random integrations
into the host genome [3,16-19].
In this study, we explored the possible use of Bifidobacte-
rium infantis as a tumor-targeting gene delivery vehicle in
bladd cancer gene therapy. Bifidobacterium infantis are
gram-positive bacteria which are non-pathogenic and
strictly anaerobic without internal and external toxin pro-
duction. It has been reported that Bifidobacterium can
inhibit tumor growth [9,15,20]. Yazawa et al confirmed
that when mammary tumors induced in rats were injected
with Bifidobacterium via the tail vein, Bifidobacterium
could propagate specifically in tumor tissuesproliferation,
resulting in tumor tissue atrophy and extending the sur-
vival of tumor-bearing rats [9,15,20]. It has also been
reported that when Bifidobacterium expressing human
endostatin were injected to tumor-bearing mice via the
tail vein, the antitumor effect was improved than the pro-
totype Bifidobacterium [5,17,19]. These reports indicate
that Bifidobacterium can be used as a tumor-targeting vec-
tor for cancer gene therapy [2-5,21]).
We have demonstrated the successful use of a novel Bifi-
dobacterium infantis-mediated tumor-targeting suicide
gene therapy system in inhibiting bladder tumor growth.
Apoptosis analysis of BI-TK/GCV treated rat bladder cancer Figure 3
Apoptosis analysis of BI-TK/GCV treated rat bladder cancer. The TUNEL assay was carried out as described in Meth-
ods. Cells with positive staining were randomly counted in 10 high-power fields and the apoptosis index was calculated (mean 
SD). (A) Normal saline group (6.88 ± 1.40), (B) Bifutobacterium infantis with empty plasmid group (16.01 ± 3.48), and (C) 
Bifutobacterium infantis-PGEX-TK group (41.72 ± 4.27). There is statistically significant difference between each groups (p < 
0.05). Representative samples are shown. Magnification, 100×.
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Our results also indicate that induced apoptosis may at
least in part account for the anticancer activity of the BI-TK
system. Apoptosis, also known as programmed cell death,
refers to certain physiological or pathological conditions
in which the end of active life is regulated by the activa-
tion of a set of apoptotic factors. In normal cells, apopto-
sis and proliferation coexist and maintain a dynamic
equilibrium. When the BI-TK/GCV suicide gene targeting
system was delivered into tumor-bearing rats, we found
that the system can significantly inhibit rat bladder tumor
growth, induce apoptosis in tumor cells, and increase Cas-
pase 3 protein. Therefore, our findings strongly suggest
that Bifidobacterium infantis-mediated tumor-targeting
suicide gene therapy system may represent a novel therapy
for bladder cancer.
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